Is NVCT or QURE more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% uniQure -1,350.73% -111.96% -29.01%

Does the media refer more to NVCT or QURE?

In the previous week, uniQure had 9 more articles in the media than Nuvectis Pharma. MarketBeat recorded 13 mentions for uniQure and 4 mentions for Nuvectis Pharma. uniQure's average media sentiment score of 0.08 beat Nuvectis Pharma's score of 0.00 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NVCT or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for Beam Therapeutics and 4 mentions for Nuvectis Pharma. Beam Therapeutics' average media sentiment score of 0.43 beat Nuvectis Pharma's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CLDX or NVCT more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.35% -47.61% Nuvectis Pharma N/A -184.25% -105.24%

Does the media refer more to CLDX or NVCT?

In the previous week, Celldex Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 7 mentions for Celldex Therapeutics and 4 mentions for Nuvectis Pharma. Celldex Therapeutics' average media sentiment score of 0.14 beat Nuvectis Pharma's score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or NVCT more profitable?

Immunome's return on equity of -50.56% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Nuvectis Pharma N/A -184.25% -105.24%

Does the media favor IMNM or NVCT?

In the previous week, Immunome had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 9 mentions for Immunome and 4 mentions for Nuvectis Pharma. Immunome's average media sentiment score of 0.61 beat Nuvectis Pharma's score of 0.00 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NRIX or NVCT?

In the previous week, Nurix Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Nurix Therapeutics and 4 mentions for Nuvectis Pharma. Nurix Therapeutics' average media sentiment score of 0.18 beat Nuvectis Pharma's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuvectis Pharma (NVCT) Competitors

$21.12 +0.99 (+4.92%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$21.12 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

NVCT vs. QURE, BEAM, CLDX, IMNM, and NRIX

Should you buy Nuvectis Pharma stock or one of its competitors? Nuvectis Pharma's main competitors and comparable companies include uniQure (QURE), Beam Therapeutics (BEAM), Celldex Therapeutics (CLDX), Immunome (IMNM), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvectis Pharma compare to uniQure?

Nuvectis Pharma (NASDAQ:NVCT) and uniQure (NASDAQ:QURE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

In the previous week, uniQure had 9 more articles in the media than Nuvectis Pharma. MarketBeat recorded 13 mentions for uniQure and 4 mentions for Nuvectis Pharma. uniQure's average media sentiment score of 0.08 beat Nuvectis Pharma's score of 0.00 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 71.64%. uniQure has a consensus target price of $53.73, indicating a potential upside of 137.84%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
uniQure	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75

Nuvectis Pharma has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market. Comparatively, uniQure has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 28.5% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nuvectis Pharma has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
uniQure	-1,350.73%	-111.96%	-29.01%

Nuvectis Pharma has higher earnings, but lower revenue than uniQure. Nuvectis Pharma is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
uniQure	$16.10M	97.33	-$198.97M	-$4.01	N/A

Summary

uniQure beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Beam Therapeutics?

Nuvectis Pharma (NASDAQ:NVCT) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Nuvectis Pharma has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Beam Therapeutics	$139.74M	19.00	-$79.99M	-$0.86	N/A

Nuvectis Pharma has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

In the previous week, Beam Therapeutics had 4 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for Beam Therapeutics and 4 mentions for Nuvectis Pharma. Beam Therapeutics' average media sentiment score of 0.43 beat Nuvectis Pharma's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the broader market.

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 71.64%. Beam Therapeutics has a consensus target price of $50.10, indicating a potential upside of 94.94%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 28.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Beam Therapeutics beats Nuvectis Pharma on 10 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

96.8% of Nuvectis Pharma shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 28.5% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celldex Therapeutics' return on equity of -52.35% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Celldex Therapeutics presently has a consensus target price of $61.92, suggesting a potential upside of 107.17%. Nuvectis Pharma has a consensus target price of $36.25, suggesting a potential upside of 71.64%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Celldex Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Celldex Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 7 mentions for Celldex Therapeutics and 4 mentions for Nuvectis Pharma. Celldex Therapeutics' average media sentiment score of 0.14 beat Nuvectis Pharma's score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

Nuvectis Pharma has lower revenue, but higher earnings than Celldex Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,524.20	-$258.76M	-$4.35	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Celldex Therapeutics beats Nuvectis Pharma on 10 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to Immunome?

Immunome (NASDAQ:IMNM) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Immunome currently has a consensus price target of $34.25, indicating a potential upside of 75.19%. Nuvectis Pharma has a consensus price target of $36.25, indicating a potential upside of 71.64%. Given Immunome's higher possible upside, research analysts clearly believe Immunome is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Immunome's return on equity of -50.56% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Nuvectis Pharma	N/A	-184.25%	-105.24%

In the previous week, Immunome had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 9 mentions for Immunome and 4 mentions for Nuvectis Pharma. Immunome's average media sentiment score of 0.61 beat Nuvectis Pharma's score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.6% of Immunome shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 28.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has lower revenue, but higher earnings than Immunome. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	319.96	-$212.39M	-$2.53	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Immunome has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

Summary

Immunome beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Nuvectis Pharma has lower revenue, but higher earnings than Nurix Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	27.62	-$264.46M	-$3.45	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Nurix Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Nurix Therapeutics and 4 mentions for Nuvectis Pharma. Nurix Therapeutics' average media sentiment score of 0.18 beat Nuvectis Pharma's score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvectis Pharma has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Nurix Therapeutics presently has a consensus price target of $34.21, suggesting a potential upside of 53.08%. Nuvectis Pharma has a consensus price target of $36.25, suggesting a potential upside of 71.64%. Given Nuvectis Pharma's higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

96.8% of Nuvectis Pharma shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 28.5% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nurix Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Summary

Nurix Therapeutics beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$657.12M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-16.12	13.42	274.15	26.16
Price / Sales	N/A	1,234.32	589.97	94.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	29.33	17.17	11.21	6.34
Net Income	-$26.44M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-3.65%	-1.33%	-0.90%	-1.41%
1 Month Performance	-6.09%	-8.44%	-4.44%	-3.48%
1 Year Performance	254.36%	14.02%	6.96%	1.16%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	1.8694 of 5 stars	$21.12 +4.9%	$36.25 +71.6%	+251.4%	$657.12M	N/A	N/A	13
QURE uniQure	3.6785 of 5 stars	$24.51 -37.3%	$58.18 +137.4%	-64.5%	$2.71B	$16.10M	N/A	221	High Trading Volume
BEAM Beam Therapeutics	2.2722 of 5 stars	$24.52 +1.2%	$49.00 +99.8%	-7.8%	$2.50B	$156.04M	N/A	540
CLDX Celldex Therapeutics	2.7939 of 5 stars	$31.64 +0.5%	$61.92 +95.7%	+8.5%	$2.47B	$1.54M	N/A	198
IMNM Immunome	3.125 of 5 stars	$21.89 +1.0%	$35.18 +60.7%	+36.8%	$2.46B	$6.94M	N/A	177

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. QURE, BEAM, CLDX, IMNM, and NRIX

How does Nuvectis Pharma compare to uniQure?

Summary

How does Nuvectis Pharma compare to Beam Therapeutics?

Summary

How does Nuvectis Pharma compare to Celldex Therapeutics?

Summary

How does Nuvectis Pharma compare to Immunome?

Summary

How does Nuvectis Pharma compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. QURE, BEAM, CLDX, IMNM, and NRIX

How does Nuvectis Pharma compare to uniQure?

Does the media refer more to NVCT or QURE?

Do analysts recommend NVCT or QURE?

Which has more volatility & risk, NVCT or QURE?

Do insiders and institutionals believe in NVCT or QURE?

Is NVCT or QURE more profitable?

Which has higher earnings and valuation, NVCT or QURE?

Summary

How does Nuvectis Pharma compare to Beam Therapeutics?

Which has preferable valuation and earnings, NVCT or BEAM?

Is NVCT or BEAM more profitable?

Does the media prefer NVCT or BEAM?

Which has more volatility and risk, NVCT or BEAM?

Do analysts prefer NVCT or BEAM?

Do insiders & institutionals hold more shares of NVCT or BEAM?

Summary

How does Nuvectis Pharma compare to Celldex Therapeutics?

Do institutionals and insiders hold more shares of CLDX or NVCT?

Is CLDX or NVCT more profitable?

Do analysts prefer CLDX or NVCT?

Does the media refer more to CLDX or NVCT?

Which has more volatility & risk, CLDX or NVCT?

Which has better earnings & valuation, CLDX or NVCT?

Summary

How does Nuvectis Pharma compare to Immunome?

Do analysts prefer IMNM or NVCT?

Is IMNM or NVCT more profitable?

Does the media favor IMNM or NVCT?

Do institutionals & insiders believe in IMNM or NVCT?

Which has better earnings & valuation, IMNM or NVCT?

Which has more volatility and risk, IMNM or NVCT?

Summary

How does Nuvectis Pharma compare to Nurix Therapeutics?

Which has preferable valuation & earnings, NRIX or NVCT?

Does the media prefer NRIX or NVCT?

Is NRIX or NVCT more profitable?

Do analysts recommend NRIX or NVCT?

Do insiders and institutionals hold more shares of NRIX or NVCT?

Which has more risk & volatility, NRIX or NVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools